Raymond J. Deshaies
Amgen Inc.
Public scientific profile · Unclaimed
Built from public scholarly sources. Expertise is inferred by ScienceWe from publications and has not been confirmed by the scientist.
Top expertise
Liver Disease Diagnosis and Treatment
Strong evidence · 3 supporting papers · latest 2025
Protein Degradation and Inhibitors
Strong evidence · 2 supporting papers · latest 2025
Endoplasmic Reticulum Stress and Disease
Strong evidence · 2 supporting papers · latest 2025
Monoclonal and Polyclonal Antibodies Research
Strong evidence · 1 supporting paper · latest 2025
Biochemical and Molecular Research
Strong evidence · 1 supporting paper · latest 2025
Ubiquitin and proteasome pathways
Strong evidence · 1 supporting paper · latest 2025
Click Chemistry and Applications
Strong evidence · 1 supporting paper · latest 2025
Lipid metabolism and biosynthesis
Strong evidence · 1 supporting paper · latest 2025
Publications (5)
Load and lock: An emerging class of therapeutics that influence macromolecular dissociation
2025DOIPMID 40839737
How multispecific molecules are transforming pharmacotherapy
2025DOIPMID 40750925
PNPLA3-I148M is a neomorph that interferes with two primary hepatic triglyceride clearance pathways
2025DOIPMID 41046517
PNPLA3-I148M is a Neomorph that Interferes with Two Primary Hepatic Triglyceride Clearance Pathways
2024DOI
Abstract 2651 PNPLA3-I148M is a Neomorph that Interferes with Two Primary Hepatic Triglyceride Clearance Pathways
2025DOI
Organizations in sourced records
Affiliation evidence only — not confirmed current employment.
- Amgen Inc.
Source: OpenAlex · retrieved 2026-09-29